Delivery Order SPE2DB20D1109-SPE2DB23FM97N
Award Date 11/3/22
Potential Completion Date 11/4/22
Potential Value $2.3K
Federal Agency
Ultimate Awardee
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $38,052.66 firm-fixed-price delivery order is for the supply of RESTASIS 0.05% eye emulsion, a specialty pharmaceutical product. The contract has an ultimate completion date of June 30, 2022. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
- This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,436.88 firm fixed-price delivery order is for RESTASIS 0.05% eye emulsion 30-count packages, with a completion date of December 4, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $6,123.83 firm fixed-price delivery order (SPE2DB22FP54M) is for the supply of RESTASIS 0.05% eye emulsion, a specialty pharmaceutical product. The contract has an ultimate completion date of July 5, 2022. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
- This federal contract award, valued at $10,247.78, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract covers the delivery of RESTASIS 0.05% eye emulsion, a prescription medication, with a completion date of May 19, 2022. This award is a delivery order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the pharmaceutical distribution company Cencora, Inc. The $7,054.00 firm fixed-price delivery order is for the supply of 4557378729 - RESTASIS 0.05% eye emulsion, a specialty medication. The contract has an ultimate completion date of May 31, 2022 and was awarded on May 30, 2022. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The $3,363.53 firm fixed-price delivery order is for the supply of RESTASIS 0.05% eye emulsion, a prescription medication used to treat dry eye disease. The contract has an ultimate completion date of May 24, 2023. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which does business as Amerisourcebergen. Cencora, Inc....
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,853.83 firm fixed-price delivery order is for the supply of RESTASIS 0.05% eye emulsion, a prescription medication. The contract has an ultimate completion date of September 10, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
- This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,620.58, is a delivery order for the supply of RESTASIS 0.05% eye emulsion. The award is not associated with any set-aside program, indicating open competition. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which does business as Amerisourcebergen. Cencora, Inc....
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, on January 3, 2022. The contract, valued at $9,109.98, is for the delivery of RESTASIS 0.05% eye emulsion. This appears to be a delivery order under a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA Troop Support Medical, valued at up to $999,999,999 and running through November 2026. The IDC serves as a primary...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,450.08 firm fixed-price delivery order is for the supply of RESTASIS 0.05% eye emulsion, a prescription medication used to treat dry eye disease. The contract has an ultimate completion date of December 8, 2022 and was awarded on December 7, 2022. Amerisourcebergen holds a significant $999,999,999 Indefinite...